The Role of Cisplatin Loaded Biocompatible Nanoparticles in Cancer Treatment

Year 2022, Volume: 43 Issue: 2, 183 - 187, 29.06.2022

Tuğba Kumtepe Murat Doğan

Abstract

Chemotherapeutic treatments focusing on cisplatin, ovarian cancer, testicular cancer, breast cancer, colon cancer, lung cancer etc. seen in adults and children. Cisplatin is an antineoplastic agent frequently used in cancer types. Drug resistance to cisplatin has an effect on the success of the treatment. After cisplatin-administered treatments, patients may experience cisplatin-induced side effects of various toxic dimensions, such as nausea, nephrotoxicity, cardiotoxicity, hepatotoxicity, and neurotoxicity. As a result of the literature review, various studies have been carried out to reduce the side effects and toxic effects of cisplatin and other anticancer molecules without interfering with their activities. In this study, we planned to prepare a cisplatin-loaded chitosan nanoparticle formulation based on the ionic gelation method using chitosan and tripolyphosphate (TPP) with the information obtained from the literature. In this study, chitosan nanoparticles containing the same concentration of cisplatin were applied to MDA-MB-231 breast cancer cell lines obtained from the American Type Culture Collection (ATCC). As a result, biocompatible nanoparticles with similar cytotoxic effects cause less side effects in other cells and tissues than other nanoparticles.

Keywords

Cancer, Cisplatin, Chitosan, Nanoparticle, Cytotoxicity.

Supporting Institution

TÜBİTAK

Project Number

1919B012002787

Thanks

I would like to state that I received support from the TUBITAK 2209 project numbered 1919B012002787 in this study. In addition, this study was performed at Cumhuriyet University Faculty of Pharmacy, Pharmaceutical Biotechnology Laboratory and Cumhuriyet University Faculty of Medicine Cancer Research Center.

References

• [1] Zhang B., Pan X., Cobb GP., Anderson TA., MicroRNAs as Oncogenes and Tumor Suppressors, Dev Biol., 302(1) (2007) 1-12.
• [2] Hanahan D., Weinberg R.A., Hallmarks of Cancer: the Next Generation, Cell, 144 (2011) 646-74.
• [3] American Cancer Society, Cancer Facts & Figures, Atlanta: American Cancer Society, 2012. Available at https://www.cancer.org/research/cancer-facts-statistic.
• [4] Lind M.J., Principles of Cytotoxic Chemotherapy, Medicine, 36(1) (2008) 19–23.
• [5] Eastman A., Improving Anticancer Drug Development Begins with Cell Culture: Misinformation Perpetrated by the Misuse of Cytotoxicity Assays, Oncotarget, 8 (2017) 8854–8866.
• [6] Donna S.S., Robert D.K., Introduction to Cancer Chemotherapeutics, Chem. Rev., 109(7) (2009) 2859–2861.
• [7] Rosenberg B., Archie W.P., Stanley T., Stephen K.C., Cisplatin: Its History and Possible Mechanisms of action, Academic Press, (1980) 9–12.
• [8] Dasari S., Tchounwou P.B., Cisplatin in Cancer Therapy: Molecular Mechanisms of action, European Journal of Pharmacology, 740(3) (2014) 64-378.
• [9] Browning R.J., Reardon P.J.T., Parhizkar M., Pedley R.B., Edirisinghe M., Knowles J.C., Stride E., Drug Delivery Strategies for Platinum-Based Chemotherapy, ACS Nano., 11(9) (2017) 8560-8578.
• [10] Tsimberidou A.M., Braiteh F., Stewart D.J., Kurzrock R., Ultimate Fate of Oncology Drugs Approved by the Us Food And Drug Administration without a Randomized Trial, Journal of Clinical Oncology, 27(36) (2009) 6243-6250.
• [11] Weiss R.B., Christian M.C., New Cisplatin Analogues in Development, Drugs, 46(3) (1993) 360-377.
• [12] Ciccarelli R.B., Solomon M.J., Varshavsky A., Lippard S.J., In vivo Effects of Cisand Trans- Diammine Dichloro Platinum (Ii) on Sv40 Chromosomes: Differential Repair, Dna-Protein Cross-Linking, and Inhibition of Replication, Biochemistry, (24) (1985) 7533–7540.
• [13] Florea A.M., Büsselberg D., Cisplatin as an Anti-Tumer Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects, Cancers, (3) (2011) 1351–1371.
• [14] Astolfi L., Ghiselli S., Guaran V., Chicca M., Simoni E., Olivetto E., Lelli G., Martini A., Correlation of Adverse Effects of Cisplatin Administration in Patients Affected by Solid Tumours: A Retrospective Evaluation, Oncol. Rep., 29 (4) (2013) 1285–1292.
• [15] Gottesman M.M., Fojo T., Bates S.E., Multidrug Resistance in Cancer: Role of ATP–Dependent Transporters, Nature Reviews Cancer, 2(1) (2002) 48-58.
• [16] Decatris M.P., Sundar S., O'Byrne K.J., Platinum-based Chemotherapy in Metastatic Breast Cancer: Current Status, Cancer Treat. Rev., (30) (2004) 53–81.
• [17] Liu H., Zang C., Fenner M.H., Possinger K., Elstner E., PPARγ Ligands and ATRA Inhibit the Invasion of Human Breast Cancer Cells in vitro, Breast Cancer Research and Treatment, 79(1) (2003) 63-74.
• [18] Libson S., Lippman M., A review of Clinical Aspects of Breast Cancer, International Review of Psychiatry, 26(1) (2014) 4-15.
• [19] Kim S., Competitive Biological Activities of Chitosan and its Derivatives Antimicrobial, Antioxidant, Anticancer, and Anti-Inflammatory Activities, International Journal of Polymer Science, 1708(172) (2018) 1-14.
• [20] Severino P., da Silva C.F., da Silva M.A., Santana M.H., Souto E.B., Chitosan Cross-Linked Pentasodium Tripolyphosphate Micro/Nanoparticles Produced by Ionotropic Gelation, Sugar Tech., 18(1) (2016) 49-54.
• [21] Kutluturkan S., Sozeri E., Uysal N., Bay F., Resilience and Burnout Status Among Nurses Working in Oncology, Ann. Gen. Psychiatry, 15(1) (2016) 1-9.
• [22] Jose S., Fangueiro J. F., Smitha J., Cinu T.A., Chacko A.J., Premaletha K., Souto E.B., Cross-linked Chitosan Microspheres for Oral Delivery of Insulin: Taguchi Design and in vivo Testing, Colloids and Surfaces B: Biointerfaces, 92(3) (2012) 175-179.
• [23] Calvo, Pilar, et al. Novel Hydrophilic Chitosan‐ Polyethylene Oxide Nanoparticles as Protein Carriers, Journal of Applied Polymer Science, 63(1) (1997) 125-132.
• [24] Wolf Nadine B., Influences of Opioids and Nanoparticles on in vitro Wound Healing Models, European Journal of Pharmaceutics and Biopharmaceutics, 73(1) (2009) 34-42.
• [25] Alp E., Yılmaz, A., Önen H. İ., Konaç E., Ekmekçi A., Menevşe E. S., Menevşe A., HeLa Hücrelerinde Sisplatinin MTOR, AKT, CCND1 ve STAT3 mRNA İfadesi Üzerine Etkileri, 31 (2020) 5-9.
• [26] Arslan, Y., Balkan, A., Avcu, F., Uçar, E., Gümüş, S., Taşçı, C., Bilgiç, H., The Evaluation of the Effectiveness of Alpha Bungarotoxin Individually and Combined with Cisplatin on A549 Lung Adenocancer Cell Line and SK-MES-1 Lung Squamous Cell Cancer Cell Line, Turk Toraks Dergisi, 20 (2019) 35.
• [27] Avcı N., Lokal Ileri Meme Kanserinin Neoadjuvan Kemoterapisinde Epirubisin, Dosetaksel ve Sisplatin Kombinasyonunun Etkinliği ve Güvenirliliği, Yüksek Lisans Tezi, Uludağ Üniversitesi, Tıp Fakültesi, (2012).
• [28] Vural B., Alkaç İ.M., Üçlü Negatif Meme Kanseri (Ünmk) Tedavisinde, Azd7762 İlacına Karşı Hassaslığın Rbfox2 Gen Ekspresyonu ile Araştırılması, Türkiye Klinikleri Tıp Bilimleri Dergisi, 41(4) (2021) 491-500.